(2E)-but-2-enedioic acid; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide

• ChemBase编号: 169210
• 分子式: C23H28N2O8
• 平均质量: 460.47702
• 单一同位素质量: 460.18456587
• SMILES: c1c(c(cc(c1)[C@H](CN[C@@H](Cc1ccc(cc1)OC)C)O)NC=O)O.C(=C\C(=O)O)/C(=O)O
• Canonical SMILES: OC(=O)/C=C/C(=O)O.O=CNc1cc(ccc1O)[C@H](CN[C@@H](Cc1ccc(cc1)OC)C)O
• InChI: InChI=1S/C19H24N2O4.C4H4O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t13-,19+;/m1./s1
• InChIKey: ZDUPYZMAPCZGJO-NSCGSSGESA-N

名称和登记号

名称

• IUPAC标准名: (2E)-but-2-enedioic acid; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide
• IUPAC传统名: arformoterol; fumaric acid; (2E)-but-2-enedioic acid; N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide
• 别名: rel-N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide Fumarate Dihydrate; Atock; Foradil; Oxeze; BD 40A; CGP 25827A; Formoterol Fumarate Dihydrate; Eformoterol; Oxis; Formoterol Fumarate

登记号

• CAS号: 73573-87-2; 183814-30-4
• PubChem SID: 162263342
• PubChem CID: 9847067

理论计算性质

• Acid pKa: 8.607353
• 质子受体: 5
• 质子供体: 4
• LogD (pH = 5.5): -1.1008605
• LogD (pH = 7.4): 0.03789571
• Log P: 1.0566727
• 摩尔折射率: 97.8715 cm^3
• 极化性: 37.3542 Å^3
• 极化表面积: 90.82 Å^2
• 可自由旋转的化学键: 10
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Methanol
• 外观: Pale Yellow Solid
• 熔点: 116-120°C

安全信息

• 保存条件: -20°C Freezer

药理学性质

• 生物活性机理: beta 2 -Adrenoceptor agonist; Bronchodilator

产品相关信息

• 成盐信息: Fumarate
• 应用领域: Antitussive agent; Bronchodilator

详细说明

Toronto Research Chemicals - F693400

Formoterol is a selective β2-adrenergic receptor agonist. Formoterol is used as an antiasthmatic.

参考文献

• Yoshida, T., et al.: Pharmacometrics, 26, 811 (1983)
• Bartow, R.A., et al.: Drugs, 55, 303 (1998)
• Murase, K. et al., Chem. Pharm. Bull., 1977, 25, 1368; 1978, 26, 1123, (synth, resoln, pharmacol)
• Tomioka, K. et al., Arch. Int. Pharmacodyn. Ther., 1981, 250, 279, (pharmacol)
• Kamimura, H. et al., J. Chromatogr., B: Biomed. Appl., 1982, 229, 337, (gc-ms)
• Sasaki, H. et al., Xenobiotica, 1982, 12, 803, (metab)
• Yamakido, M. et al., Int. J. Clin. Pharmacol., Ther. Toxicol., 1985, 23, 461, (pharmacol)
• Subramanian, N., Arzneim.-Forsch., 1986, 36, 502, (pharmacol)
• Tasaka, K., Drugs of Today (Barcelona), 1986, 22, 505, (rev)
• Anderson, G.P., Agents Actions, Suppl., 1991, 34, 97, (rev)
• Trofast, J. et al., Chirality, 1991, 3, 443, (synth, pharmacol)
• Faulds, D. et al., Drugs, 1991, 42, 115, (rev)
• Anderson, G.P., Life Sci., 1993, 52, 2145, (rev)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 1244
• Nials, A.T. et al., Eur. J. Pharmacol., 1994, 251, 127, (pharmacol)
• Van den Berg, B.T. et al., Ther. Drug Monit., 1994, 16, 196, (hplc)
• Kurihara, H. et al., Acta Cryst. C, 1997, 53, 1887-1889, (1'R,4'R-form, cryst struct)
• Hett, R. et al., Tet. Lett., 1997, 38, 1125, (synth, isomers, bibl)
• Bartow, R.A. et al., Drugs, 1998, 55, 303-322, (rev)
• Shinkai, N. et al., J. Pharm. Pharmacol., 2000, 52, 1417-1423, (tox)
• McGavin, J.R. et al., Drugs, 2001, 61, 71-78, (rev.)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, FNE100